This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

J&J Slumps on Soft Outlook

Updated from 3:12 p.m. EST

Johnson & Johnson's (JNJ - Get Report) shares closed to the downside Tuesday amid a weak forecast from the company and a down day overall for the U.S. stock market.

The New Jersey-based drug and consumer-products giant predicted earnings for 2009 of $4.45 to $4.55 a share, which excludes the impact of certain items, but includes a reduction of 3 cents to 5 cents from the pending acquisition of Mentor (MNT). On average, analysts surveyed by Thomson Reuters are calling for $4.61.

J&J's outlook came as the company reported fourth-quarter earnings of $2.7 billion, or 97 cents a share. Before items, the company would have earned 94 cents, 2 cents better than expectations. In the same quarter last year, J&J had a profit of $2.4 billion, or 82 cents a share.

Worldwide sales in the quarter fell 4.9% year over year to $15.2 billion, a decline that was primarily attributable to unfavorable exchange rates, and missed Wall Street's $15.9 billion consensus estimate. Sales rose 4.3% for the full year to $63.7 billion, and adjusted earnings were $4.55 a share.

Shares of J&J closed down 69 cents, or 1.2%, to $56.75, after at one point being one of only four stocks in the Dow Jones Industrial Average that was up for the day, along with Merck (MRK - Get Report), AT&T (T - Get Report) and Verizon (VZ - Get Report).

J&J peers Pfizer (PFE - Get Report) and Procter & Gamble (PG - Get Report) were slightly lower.
This article was written by a staff member of

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
JNJ $100.54 -3.23%
MRK $49.38 1.63%
PFE $29.03 0.10%
PG $81.20 0.62%
T $36.88 0.96%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs